Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210593
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Stock-based compensation expense | 5,484 | 1,839 |
| Non cash operating lease expense | 34 | 29 |
| Accretion and amortization of marketable securities, net | (579) | (1,343) |
| Depreciation expense | 64 | 77 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (725) | 1,648 |
| Accounts payable | 3,972 | (1,564) |
| Accrued expenses | (4,857) | 558 |
Item 1. Financial Statements.
FAQ
- What is MBX Biosciences, Inc.'s D&A?
- MBX Biosciences, Inc. (MBX) reported D&A of $64K in Q1 2026.
- How has MBX Biosciences, Inc.'s D&A changed year-over-year?
- MBX Biosciences, Inc.'s D&A decreased by 16.9% year-over-year, from $77K to $64K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about MBX Biosciences, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude